Covid Vaccine Glass Tubing Manufacturer Schott Invests 70 Million Euros In A Facility In Gujarat
by
Excerpt: SCHOTT Glass India, a leading German speciality glass manufacturer, has announced a 70 million euro investment to expand its Gujarat tubing factory, which currently produces FIOLAX glass, which is used in Covid-19 vaccine packaging in India. SCHOTT’s glass tubing is used to package about 95% of Covid-19 vaccinations in India, according to the […]
South Korean Companies Plan To Invest US$5.4 Billion To Build Vaccination Centre By 2024
by
Excerpt To make South Korea a K-global COVID vaccine hub, the government is dedicated to cultivating and aiding the vaccine industry. South Korea’s government wants to make it a worldwide vaccine production and distribution hub. Furthermore, by 2024, the private sector has committed to invest a record US$5.4 Billion. At the meeting, the government decided […]
Uzbekistan has established Central Asia’s largest Cold Chain Vaccine Facility
by
Excerpt UNICEF has supported the building of supply and cold chain systems at both national and local levels in Uzbekistan, including through mobile teams, for the past four years, thanks to funding from Gavi, the Vaccine Alliance. UNICEF handed over the Republican Cold Chain Warehouse, Central Asia’s largest vaccine facility, to the Uzbek […]
The Covaxin COVID-19 Vaccine from Bharat Biotech has been approved by the WHO for emergency use.
by
Excerpt: COVAXIN® (produced by Hyderabad-based Bharat Biotech) received an emergency use listing (EUL) from the World Health Organization (WHO) today, adding to a growing portfolio of vaccines certified by WHO for the prevention of COVID-19 caused by SARS-CoV-2. The vaccine is being developed using a platform derived from Whole-Virion Inactivated Vero Cells. Because inactivated […]
Pfizer announces the start of phase 3 clinical trials in adults for its investigational vaccine against Respiratory Syncytial Virus (RSV)
Pfizer has initiated RENOIR, a Phase 3 clinical trial of the Respiratory Syncytial Virus (RSV) bivalent prefusion F subunit investigational vaccine candidate in adults ages 60 or older. RSV is a contagious, seasonal illness, and a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available. The candidate […]
Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day
Moderna announces significant advancements to be presented at its annual R&D Day, including a combination booster vaccine for COVID-19 and seasonal flu, a pediatric combination candidate for RSV and hMPV, promising interim Phase 1 data for an RSV vaccine candidate, an infectious disease therapeutic vaccine candidate, and full enrolment for a Phase 2 study of […]
Novavax Initiates Phase 1/2 Clinical Trial Combination Vaccine for COVID-19 and Seasonal Influenza
Excerpt Novavax has enrolled the first participants in a Phase 1/2 clinical trial of a combination vaccine using its seasonal influenza and COVID-19 vaccines, together with its patent saponin-based Matrix-M TM adjuvant. Both vaccines have individually demonstrated strong results. The study will evaluate the immunogenicity and safety of multiple formulations of the combination vaccine administered […]
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps
by
Excerpt The FDA has approved GSK’s Nucala (mepolizumab) as an add-on treatment in the US for adults with chronic rhinosinusitis with nasal polyps (CRSwNP). Mepolizumab is the first anti- interleukin-5 therapy to be approved for CRSwNP, which affects over 5 million in the US, caused by raised eosinophil levels resulting in the formation of nasal […]
IVI Partners with SK Bioscience to Conduct Late Stage Global Clinical Trials of SK Bioscience’s Recombinant Protein Vaccine Candidate (GBP510)
Excerpt The International Vaccine Institute (IVI) will be conducting Phase 3 clinical trials of SK bioscience’s recombinant protein vaccine candidate (GBP510) in Europe and Southeast Asia, with the aim of bringing it to market in 2022. Additionally, IVI has formed a partnership with SK and the Korean National Institute of Health (KNIH) to jointly conduct […]
SINOVAC Announces Positive Data on Booster Dose of CoronaVac ®
by
Excerpt Results from an ongoing phase 2 clinical trial studying immunogenicity, safety, and immune persistence of CoronaVac ® show that while good immune memory is generated after the second dose, a third dose induces a stronger immune response, with an even lower adverse reaction rate after the third dose as compared to the second. A […]
Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases
by
Excerpt Vigil Neuroscience has secured $90 million in its Series B financing led by Vida Ventures with participation from new as well as existing investors. This will propel the advancement of Vigil’s proprietary microglia-focused medicine line-up for the treatment of neurodegenerative diseases. Development of the antibody, VGL101, and triggering receptor on myeloid cells 2 (TREM2) […]
